ClinicalTrials.gg
CompletedNCT02726100Updated Mar 12, 2021

SMARTHealth Diabetes in China Using Lay Family Health Promoters

An interventional study of SMARTHealth Diabetes in Diabetes Mellitus, Type 2, Hypertension and Dyslipidemias, sponsored by The George Institute for Global Health, China. Completed at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-12.

Sponsored by The George Institute for Global Health, China · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,073
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
41st of 769
2,073 · median 192
Started
2017
with 45 others
No phase
195 of 913
55 open now
Registered
248th of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 41st largest by enrollment of the 769 interventional ones that give a count, is one of 46 that started in 2017, is one of 195 with no phase, and was the 248th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

It's a community-based parallel-arm cluster Randomized Controlled Trial (RCT). An interactive mobile health management system will be developed to support lay family health promoters and healthcare staff to improve clinical outcomes for family members with Type 2 Diabetes Mellitus (T2DM). 2,000 participants from 80 sites will be chosen from urban (40 communities) and rural (40 villages) settings in Shijiazhuang City, Hebei Province.

Read the detailed description

Study design and Settings:

Cluster randomised controlled trial involving 80 sites (40 communities in urban Shijiazhuang and 40 villages in rural Shijiazhuang) and 2,000 people with T2DM.

Hypothesis:

An interactive mobile health management system can support lay family health promoters (FHP) and healthcare staff to improve clinical outcomes for family members with T2DM

Intervention:

SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM. It comprises the following core features:

  • Management support based on best practice clinical guidelines
  • Self-management tools and resources for family members
  • Password protected registration of patients and their nominated FHP to access this information
  • Population of key clinical information into a desktop application used by health care providers when applicable

Community eligibility:

  • 40 urban communities and 40 rural villages from geographically dispersed regions will be selected
  • Each community/ village must have at least one community health station providing services to ≥1,000 adult residents
  • Staff at the community health station must be willing to participate in the intervention

Statistical power:

80 clusters and a mean community cluster size of 25 participants (2,000 total) will provide 90% power to detect an absolute improvement of 10% in the primary outcome. This assumes 20% of people in the control arm will achieve ≥2 'ABC' diabetes goals ((HbA1C\<7%; Blood Pressure \<140/80 mmHg, LDL cholesterol \<100mg/dl or 2.6mmol/L) at end of study; an intra-class correlation coefficient of 0.05, a 20% loss to follow-up, and a 2-sided significance level of 0.05. This translates to a mean reduction of 0.35% for HbA1C, 0.14 mmol/L for LDL cholesterol and 3.4mmHg for systolic BP. Primary analyses will be conducted at the patient level. Secondary analyses will be conducted at the cluster level. Sub-group analyses will be conducted at the community level (based on size and health service characteristics) and patient level (based on demographic factors (co-habitation with FHP) and clinical factors (control rate of 'ABC' risk factors at baseline).

Significance:

The Chinese government has placed prevention and treatment of diabetes as one of 11 National Basic Public Health Services. Despite great promise for mobile health (mHealth) interventions to improve access to effective healthcare, there remains uncertainty about how this can be successfully achieved. These uncertainties pose substantial dilemmas for health system planners. The findings are likely to inform policy on a scalable strategy to overcome sub-optimal access to effective health care in China.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertension
  • Dyslipidemias

Keywords

  • Telemedicine
  • Diabetes Mellitus, Type 2
  • Decision Support Systems, Clinical
  • Family Health Promoter
  • Primary Health Care
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established T2DM
  • >= 7%
  • Nominated family member with mobile internet access who agrees to be a family health promoter (FHP)
  • Able to provide

Exclusion criteria

Exclusion Criteria:

Psychologically or physically unable to participate the trials.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
2,073 participants (actual)

Study arms

  • Experimental
    Intervention arm

    Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.

    Behavioral: SMARTHealth Diabetes

  • No intervention
    Control arm

    Control group doesn't use SMARTHealth Diabetes.The "usual-care" in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance.

Interventions

  • BehavioralSMARTHealth Diabetes

    SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving at least two "ABC" goals

    The proportion of patients achieving at least two "ABC" goals defined as any two of the following: HbA1c \<7.0%, blood pressure (BP) \<140/80mmHg and LDL cholesterol \<100mg/dl or 2.6mmol/L) at 24 months

    Time frame: 24 months

Secondary outcomes

  1. The proportion of patients achieving the "A" goal

    The proportion of patients achieving HbA1c \<7.0% at 24 months

    Time frame: 24 months

  2. The proportion of patients achieving the "B" goal

    The proportion of patients achieving blood pressure (BP) \<140/80mmHg at 24 months

    Time frame: 24 months

  3. The proportion of patients achieving the "C" goal

    The proportion of patients achieving LDL cholesterol \<100mg/dl or 2.6mmol/L at 24 months

    Time frame: 24 months

  4. The proportion of patients achieving FPG<7.0 mmol/L

    The proportion of patients achieving FPG\<7.0 mmol/L at 24 months

    Time frame: 24 months

  5. Mean change in HbA1c level

    Mean change in HbA1c level from baseline to 24 months

    Time frame: 24 months

  6. Mean changes in systolic and diastolic blood pressure levels

    Mean changes in systolic and diastolic blood pressure levels from baseline to 24 months

    Time frame: 24 months

  7. Mean change in LDL cholesterol level

    Mean change in LDL cholesterol level from baseline to 24 months

    Time frame: 24 months

  8. Mean change in FPG level

    Mean change in FPG level from baseline to 24 months

    Time frame: 24 months

  9. Mean change in the Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 month

    The Summary of Diabetes Self-Care Activities is a scale to measure patients' self-management. The minimum value of each scale item is 0 and the maximum value is 7. Higher scores mean a better outcome.

    Time frame: 24 months

Other outcomes

  1. Mean change in body mass index (BMI)

    Mean change in body mass index (BMI) from baseline to 24 months

    Time frame: 24 months

  2. Mean change in waist circumstance (WC)

    Mean change in waist circumstance (WC) from baseline to 24 months

    Time frame: 24 months

  3. Mean change in the European quality of life 5 dimensions 3 levels scale (EQ-5D-3L) index value

    Mean change in the European quality of life 5 dimensions 3 levels scale (EQ-5D-3L) index value from baseline to 24 months. The minimum value of the scale is 0 and the maximum value is 1. Higher scores mean a better outcome.

    Time frame: 24 months

  4. Mean change in the European quality of life overall self-rated visual analogue scale (EQ-VAS)

    Mean change in the European quality of life overall self-rated visual analogue scale (EQ-VAS) from baseline to 24 months. The minimum value of the scale is 0 and the maximum value is 100. Higher scores mean a better outcome.

    Time frame: 24 months

  5. Mean change in The Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 months

    Pending

    Time frame: 24 months

  6. Mean change in urine albumin creatinine ratio (ACR)

    Mean change in urine albumin creatinine ratio (ACR) from baseline to 24 months

    Time frame: 24 months

  7. Mean change in estimated glomerular filtration rate (GFR)

    Mean change in estimated glomerular filtration rate (GFR) from baseline to 24 months

    Time frame: 24 months

07

Study locations

2 sites
  • Hebei Medical University
    Shijiazhuang, Hebei 050017, China
  • Center of Disease Control and Prevention, Luquan
    Shijiazhuang, Hebei 050200, China
08

References and documents

Publications

  • Peiris D, Sun L, Patel A, Tian M, Essue B, Jan S, Zhang P. Systematic medical assessment, referral and treatment for diabetes care in China using lay family health promoters: protocol for the SMARTDiabetes cluster randomised controlled trial. Implement Sci. 2016 Aug 17;11(1):116. doi: 10.1186/s13012-016-0481-8. PubMed 27535128 ↗

Individual participant data

Plan to share: No — Data are only accessed by investigators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Oct 2019, 26 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 26 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2016
First posted
Apr 1, 2016
StartActual
Aug 1, 2017
Primary completionActual
Oct 19, 2019
CompletionActual
Feb 28, 2021
Last update
Mar 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02726100
Lead sponsor
The George Institute for Global Health, China
Collaborators
Global Alliance for Chronic Diseases (GACD), National Health and Medical Research Council, Australia
Responsible party
Puhong Zhang (Associate Director, The George Institute for Global Health, China) — Principal investigator
First posted
Apr 1, 2016
Start date
Aug 1, 2017
Primary completion
Oct 19, 2019
Completion
Feb 28, 2021
Last update
Mar 12, 2021

Study contacts

Puhong Zhang, PhD
principal investigator · The George Institute for Global Health at Peking University Health Science Center
David Peiris, PhD
principal investigator · The George Institute for Global Health, University of Sydney

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion